Ajanta Pharma has entered into a strategic in-licensing agreement with Biocon Limited for the supply of Semaglutide, a GLP-1 receptor agonist used to improve glycemic control in adults with type-2 diabetes. The agreement was announced through a regulatory filing under Regulation 30 on December 23, 2025.

Agreement Structure and Geographic Coverage

Under the comprehensive licensing agreement, Biocon will supply its vertically integrated drug product Semaglutide to Ajanta Pharma for marketing across 26 countries in Africa, the Middle East and Central Asia. The arrangement provides Ajanta Pharma with exclusive marketing rights in 23 countries and semi-exclusive marketing rights in the remaining 3 countries.

Strategic Benefits for Ajanta Pharma

The collaboration represents a strategic step for Ajanta Pharma to expand its portfolio with a high-growth GLP-1 therapy while leveraging its strong commercial reach across the target regions. The agreement provides an efficient pathway to accelerate market access for Semaglutide in regions where Ajanta Pharma has established market presence.

Ajanta Pharma has established itself as a leading Indian pharmaceutical company with a branded generic business presence in over 30 countries across Africa, South-East Asia, Central Asia and Middle East. The company maintains a strong presence across diverse therapeutic segments including cardiology, anti-diabetes, ophthalmology, antibiotic, anti-malarial, pain management, gynaecology, paediatric care, and general health products.

Management Commentary

Yogesh Agrawal, Managing Director of Ajanta Pharma Limited, noted that GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. He expressed confidence in building Semaglutide into a meaningful and high-growth brand across these countries, leveraging Ajanta Pharma's strong on-ground presence and deep market reach.

Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Limited, emphasized the strategic importance of the partnership in expanding the global footprint of Biocon's GLP-1 portfolio. He highlighted that the collaboration will enable broader and more affordable access to Semaglutide for patients in these regions.

Company Profiles and Market Position

Ajanta Pharma operates a state-of-the-art R&D center in Mumbai and maintains seven world-class manufacturing facilities located in India. The company markets more than 220 brands in emerging markets, with many holding leadership positions in their therapeutic and sub-therapeutic segments, supported by over 2,000 medical representatives across target regions.

Biocon Limited, publicly listed in 2004, is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets.

Ajanta Pharma Limited , a prominent pharmaceutical company, has reported significant developments in its shareholding structure. Two promoters of the company have released pledges on their shares, as disclosed in recent regulatory filings.

Key Details of the Pledge Releases

Latest Regulatory Filing Details

According to the latest regulatory disclosure, Aayush Agrawal, acting as Trustee of Aayush Agrawal Trust, has formally communicated the pledge release to both BSE Limited and National Stock Exchange of India. The disclosure was made under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance

Ajanta Pharma has adhered to the regulatory requirements by making the necessary disclosures to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). These actions align with the Securities and Exchange Board of India (SEBI) regulations, specifically under the substantial acquisition and takeover regulations.

Implications of Pledge Releases

The release of pledged shares typically indicates a positive development for the company and its shareholders. It suggests that the promoters have been able to fulfill financial obligations or have found alternative means of financing, reducing the overall encumbrance on the company's shares. The specific mention of "upward movement in market price" as a reason for Aayush Agrawal's pledge release indicates favorable market conditions for the stock.

Transparency in Corporate Governance

By promptly disclosing this information, Ajanta Pharma demonstrates its commitment to transparency and good corporate governance practices. Such disclosures help investors and market participants make informed decisions based on the latest changes in the company's shareholding pattern. The regulatory filings include detailed information about the share encumbrance releases, as mandated by SEBI's substantial acquisition and takeover regulations.